Urethral cancer staging

Jump to: navigation, search

Urethral cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Urethral cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Urethral cancer staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Urethral cancer staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Urethral cancer staging

CDC on Urethral cancer staging

Urethral cancer staging in the news

Blogs on Urethral cancer staging

Directions to Hospitals Treating Urethral cancer

Risk calculators and risk factors for Urethral cancer staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The staging of urethral cancer is based on the TNM staging system.

Staging

Definitions of TNM [1]

The American Joint Committee on Cancer has designated staging by TNM classification to define urethral cancer.

TNM Definition
TX Primary tumor cannot be assessed.
T0 No evidence of primary tumor.
Ta Noninvasive papillary, polypoid, or verrucous carcinoma.
Tis Carcinoma in situ.
T0 No evidence of primary tumor.
T1 Tumor invades subepithelial connective tissue.
T2 Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle.
T3 Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck.
T4 Tumor invades other adjacent organs.
Urothelial (Transitional Cell) Carcinoma of the Prostate
Tis
pu
Carcinoma in situ, involvement of the prostatic urethra.
Tis
pd
Carcinoma in situ, involvement of the prostatic ducts.
T1 Tumor invades urethral subepithelial connective tissue.
T2 Tumor invades any of the following: prostatic stroma, corpus spongiosum, periurethral muscle.
T3 Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, bladder neck (extraprostatic extension).
T4 Tumor invades other adjacent organs (invasion of the bladder).
other adjacent organs.
Regional Lymph Nodes
NX Regional lymph nodes cannot be assessed.
N0 No regional lymph node metastasis.
N1 Metastasis in a single lymph node 2 cm or less in greatest dimension.
N2 Metastasis in a single node more than 2 cm in greatest dimension, or in multiple nodes.
Distant Metastasis
M0 No distant metastasis.
M1 Distant metastasis.
Urethra. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 508-9.

Anatomic Stage

Stage T N M
0a Ta N0 M0
0is Tis N0 M0
Tis
pu
N0 M0
Tis
pd
N0 M0
I T1 N0 M0
II T2 N0 M0
III T1 N1 M0
T2 N1 M0
T3 N0 M0
T3 N1 M0
IV T4 N0 M0
T4 N1 M0
Any T N2 M0
Any T Any N M0
Urethra. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 508-9.


References

  1. National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq

Linked-in.jpg